Perrigo Company Plc Stock Today
| PRGO Stock | USD 24.49 0.31 1.25% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Perrigo Company is selling at 24.49 as of the 16th of February 2025; that is 1.25 percent decrease since the beginning of the trading day. The stock's open price was 24.8. Perrigo Company has about a 41 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Note, on September 12, 2016, Senator James Inhofe of US Senate acquired $50k to $100k worth of Perrigo Company's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of December 1991 | Category Healthcare | Classification Health Care |
Perrigo Company plc provides over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. The company has 136.43 M outstanding shares of which 5.29 M shares are at this time shorted by private and institutional investors with about 3.87 trading days to cover. More on Perrigo Company PLC
Moving together with Perrigo Stock
Moving against Perrigo Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Perrigo Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Patrick LockwoodTaylor | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Perrigo Company plc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Pharmaceutical, SP Midcap 400, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal TestingCatholic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPerrigo Company can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Perrigo Company's financial leverage. It provides some insight into what part of Perrigo Company's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Perrigo Company PLC (PRGO) is traded on New York Stock Exchange in USA. It is located in The Sharp Building, Dublin, Ireland, D02 TY74 and employs 9,140 people. Perrigo Company is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.34 B. Perrigo Company conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 136.43 M outstanding shares of which 5.29 M shares are at this time shorted by private and institutional investors with about 3.87 trading days to cover.
Perrigo Company PLC currently holds about 490.4 M in cash with 405.5 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.64.
Check Perrigo Company Probability Of Bankruptcy
Ownership AllocationThe majority of Perrigo Company PLC outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Perrigo Company to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Perrigo Company. Please pay attention to any change in the institutional holdings of Perrigo Company as this could imply that something significant has changed or is about to change at the company. On September 12, 2016, Senator James Inhofe of US Senate acquired $50k to $100k worth of Perrigo Company's common stock.
Check Perrigo Ownership Details
Perrigo Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Perpetual Ltd | 2024-12-31 | 2.4 M | |
| Copeland Capital Management, Llc | 2024-12-31 | 2.4 M | |
| Geode Capital Management, Llc | 2024-09-30 | 2.4 M | |
| Bank Of America Corp | 2024-09-30 | 2.2 M | |
| Diamond Hill Capital Management Inc | 2024-09-30 | 1.9 M | |
| Ion Asset Management Ltd. | 2024-09-30 | 1.9 M | |
| Philosophy Capital Management Llc | 2024-09-30 | 1.8 M | |
| Fmr Inc | 2024-09-30 | 1.8 M | |
| Clearline Capital Lp | 2024-09-30 | 1.6 M | |
| Vanguard Group Inc | 2024-09-30 | 14.9 M | |
| Blackrock Inc | 2024-09-30 | 13 M |
Perrigo Company Historical Income Statement
Perrigo Stock Against Markets
Perrigo Company Corporate Directors
| Orlando Ashford | Independent Director | Profile | |
| Donal OConnor | Independent Director | Profile | |
| Adriana Karaboutis | Independent Director | Profile | |
| Jeffrey Kindler | Independent Director | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Perrigo Company PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Perrigo Company. If investors know Perrigo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Perrigo Company listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.64) | Dividend Share 1.101 | Earnings Share (1.07) | Revenue Per Share | Quarterly Revenue Growth (0.03) |
The market value of Perrigo Company is measured differently than its book value, which is the value of Perrigo that is recorded on the company's balance sheet. Investors also form their own opinion of Perrigo Company's value that differs from its market value or its book value, called intrinsic value, which is Perrigo Company's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Perrigo Company's market value can be influenced by many factors that don't directly affect Perrigo Company's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Perrigo Company's value and its price as these two are different measures arrived at by different means. Investors typically determine if Perrigo Company is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Perrigo Company's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.